Loading
In8bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Graff Jeremy R., was filed 15 Sept 2023.
In8bio, Inc.: what insiders have been doing
In8bio, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 7 filings came from 6 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 7 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 49 purchases against no sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -19.4 m USD.
Over the last twelve months, not one insider purchase of In8bio, Inc. stock was filed. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€10M
49 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -68.0%Entry US$28.68 · Close at T+365 US$9.18
- -52.7%Entry US$33.27 · Close at T+365 US$15.75
- -52.7%Entry US$33.27 · Close at T+365 US$15.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.12
Analyst consensus
3 analysts1.33/5
US$5.00Target US$7.00(+523%)US$10.00
Income statement
EBITDA-US$17.4M
Net income-US$19.4M0.0% margin
Valuation
PER (forward)-1.2x
P/Book0.6x
Beta0.30
Balance sheet & cash
Market capUS$11.1M
Total debtUS$2.8M
Free Cash Flow-US$12.7M
Debt / Equity12%
Profitability & ownership
ROE-111.1%
ROA-58.4%
% insiders7.6%
% institutions38.4%
Last declaration on 29 May 2026
Declarations95 total
724,637 shares0Common StockSEC:0001682638-26-000006:0
7,247 shares@ US$1.3839.2% of flowCommon StockSEC:0001874384-25-000003:0
36,232 shares@ US$1.3837.1% of flowCommon StockSEC:0001830914-25-000003:0
724,637 shares@ US$1.3836.7% of flowCommon StockSEC:0001682638-25-000004:0
36,232 shares@ US$1.3839.3% of flowCommon StockSEC:0001643070-25-000005:0
7,247 shares@ US$1.3841.9% of flowCommon StockSEC:0001898521-25-000003:0
72,464 shares@ US$1.3828.9% of flowCommon StockSEC:0001434099-25-000004:0
11,000 shares@ US$0.18441.6% of flowCommon StockSEC:0001415889-25-012287:1
81,967 shares@ US$0.18444.5% of flowCommon StockSEC:0001415889-25-012286:0
15,000 shares@ US$0.184411.2% of flowCommon StockSEC:0001415889-25-012288:0
12,295 shares@ US$0.18449.8% of flowCommon StockSEC:0001415889-25-012289:0
102,459 shares@ US$0.184415.4% of flowCommon StockSEC:0001415889-25-012287:0
126,582 sharesCommon StockSEC:0001415889-24-024866:0
253,164 sharesCommon StockSEC:0001415889-24-024867:0
25,316 sharesCommon StockSEC:0001415889-24-024869:0
25,316 sharesCommon StockSEC:0001415889-24-024871:0
126,582 sharesCommon StockSEC:0001415889-24-024868:0
81,967 sharesCommon StockSEC:0001209191-23-058720:0
102,459 sharesCommon StockSEC:0001209191-23-058719:0
1,639 sharesCommon StockSEC:0001209191-23-058714:0
12,295 sharesCommon StockSEC:0001209191-23-058716:0
20,492 sharesCommon StockSEC:0001209191-23-058717:0
81,967 sharesCommon StockSEC:0001209191-23-058718:0
2,049 sharesCommon StockSEC:0001209191-23-058721:0
4,098 sharesCommon StockSEC:0001209191-23-058715:0
25 of 95 declarations
About In8bio, Inc.
IN8bio, Inc. (ticker: INAB) is a clinical-stage biopharmaceutical company listed on the Nasdaq market in the United States. For French-speaking investors, this is an innovative but highly speculative healthcare name focused on cellular immuno-oncology. The company develops gamma-delta (γδ) T-cell therapies, a subset of immune cells that it believes may offer a differentiated way to fight cancer while addressing some of the limitations of conventional approaches. IN8bio was founded in 2016 with the mission of developing next-generation therapies for cancer, and its scientific roots are tied to co-founder Lawrence Lamb’s work in gamma-delta T-cell biology. The company is headquartered in New York, New York, with primary scientific operations in Birmingham, Alabama, reflecting a common U.S. biotech setup in which corporate, capital-markets and R&D functions are split across locations.
The core of IN8bio’s investment case is its proprietary DeltEx™ platform, which underpins a diversified set of product concepts, including autologous, allogeneic, iPSC-derived and genetically modified γδ T-cell therapies. The platform is designed to support both solid tumors and hematologic cancers, with a particular emphasis on high-unmet-need indications such as glioblastoma and certain leukemia settings. More recently, management has also highlighted a next-generation gamma-delta T-cell engager program, expanding the platform’s scope beyond oncology and into selected autoimmune disease applications. In other words, IN8bio is still primarily a clinical and scientific story: unlike commercial-stage biopharma companies, its valuation is driven far more by clinical data, manufacturing reproducibility, intellectual property and financing capacity than by current sales.
Read moreShow less
From a competitive standpoint, IN8bio operates in a crowded and fast-moving cell-therapy landscape where several companies are trying to prove superior efficacy, safety and scalability. Its differentiation lies in the γδ biology angle, which the company positions as potentially offering advantages such as lower cytokine-release risk compared with some traditional T-cell engager or CAR-T approaches. Recent corporate developments have been important. In 2025 and 2026, management discussed progress across its INB-100, INB-200/400 and INB-600 programs, along with a private placement announced in December 2025 to help fund development of the INB-619 T-cell engager. In March 2025, the company also highlighted durable responses seen in its clinical programs. For investors, the key watchpoints remain clinical readouts, cash runway, dilution risk and the company’s ability to translate a promising scientific platform into reproducible, registrable clinical outcomes.
